AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: ELIQUIS (apixaban) (eliquis.com)
Eliquis presents a regulatory fortress built on a technical swamp. While the safety data is dense and high-substance, the 75% failure rate of its internal clinical navigation makes the site’s claims of being a primary resource for patients feel like hollow marketing.
Immediately resolve the 404 errors on the /vte/, /pediatric/, and /afib/ sub-pages to restore the promised signal. Implement Organization and Drug schema to provide a machine-readable authority footprint. Replace the generic review count widget with links to actual peer-reviewed clinical trial results. Add a specific source citation (e.g., IMS health data) with a date for the ‘#1 Prescribed’ claim to move it from fluff to substance.
The site exhibits high information density in its safety disclosures, with technical passages describing spinal or epidural blood clots and specific medication interactions (NSAIDs, SSRIs). However, the primary H1 ‘THE #1 PRESCRIBED ORAL BLOOD THINNER’ is a bold power claim lacking an immediate numerical citation or data source in the text. Substance is found in the granular dosage descriptions and pediatric weight-based instructions (less than 77 pounds), which provide high technical utility compared to generic marketing fluff.
Most sites "have schema," but AI still cannot understand what their pages represent. Run a Structured Data AI Audit to see what entity types your pages actually resolve into.
There is catastrophic semantic drift between the homepage signal and the sub-page delivery. The homepage H3 headings promise dedicated sections for ‘Atrial Fibrillation (AFib)’, ‘Deep Vein Thrombosis (DVT)’, and ‘Pediatric Patients,’ yet the corresponding URLs (/afib/, /vte/, /pediatric/) all return ‘Page Not Found’ errors. This represents a 75% failure rate in the site’s promise to provide specific clinical information for its advertised indications.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site triggers a major trust theatre flag with a review_count of 7 on the homepage and 6 on 404 pages, yet a proof_links_count of 0. Displaying review metrics without verifiable links to patient testimonials or clinical trial data in a pharmaceutical context is a high-BS signal. The claim of being the ‘#1 prescribed’ medication remains an unsubstantiated performance claim within the provided crawl data.
The proof density is lopsided; legal and safety evidence is overwhelming (citing specific adverse effects like ‘hematoma’ and ‘paralysis’), but clinical proof for efficacy is entirely missing from the crawl due to the failed sub-pages. There are 0 external proof paths to peer-reviewed studies or ClinicalTrials.gov registrations in the provided evidence.
For a demonstration of entity driven retail architecture, open the Walmart Structured Data audit. View the Walmart Structured Data Audit to see how product, brand, and service entities are reconstructed for AI systems.
While the core safety text is highly specific to the molecule apixaban, the 404 pages utilize entirely generic template language (‘We are sorry. The page you requested… did not load properly’). The value proposition of support programs like ‘ELIQUIS 360 Support’ follows standard industry cliches but is anchored by specific offers like the ‘Free 30-day trial offer,’ which prevents a maximum commodity penalty.
There is a significant authority gap due to the complete absence of structured data (schema_json is null) and a broken technical hierarchy where 3 out of 4 primary pages fail to resolve. While the site references the FDA and healthcare providers, it lacks Person schema or sameAs links for medical directors or clinical leads, relying entirely on the brand’s weight rather than verifiable expert footprints.
The disconnect between the marketing claim ‘THE #1 PRESCRIBED ORAL BLOOD THINNER’ and the site’s technical state is severe. A market leader should demonstrate technical excellence, yet the site fails to provide the basic infrastructure to support its primary therapeutic claims. The marketing tone is authoritative, but the content delivery is broken.
Medical Devices, Pharma & Biotech BS: ELIQUIS (apixaban) (eliquis.com)
The site strongly matches the Pharma & Biotech category, characterized by extensive mandatory safety disclosures and clinical indications. The presence of Boxed WARNINGS and specific dosage strengths (2.5 mg and 5 mg) confirms its role as a regulated prescription medicine platform.
Before embeddings, before entities, before retrieval — the crawler must reach the text. Open the Crawlability & Indexation Guide to learn how access failures erase meaning long before interpretation begins.
“The score is driven primarily by the total collapse of Semantic Coherence and Identity & Authority. While Information Density is high for safety content, the technical failure of the sub-pages (404 errors) and the presence of unverified review counts (Trust Theatre) create a high BS-profile despite the brand's legitimate pharmaceutical status.”